Wait, we have a special offer for you! ✋

Get your exclusive discount now

YES, get the discount! No, I'd pay the full price
Coronavirus (COVID-19) Current Therapy Global Market Opportunities And Strategies To 2034

Coronavirus (COVID-19) Current Therapy Market 2025 – By Drug Type (Antivirals, Monoclonal Antibodies (Mabs), Corticosteroid, Supplements, Antimalarial, Interferons And Interleukin Inhibitors, Other Anti Infections, Others), By Route Of Administration (Oral, Intravenous), By End User (Hospitals, Clinics, Home Care, Other End Users), And By Region, Opportunities And Strategies – Global Forecast To 2035

Coronavirus (COVID-19) Current Therapy Global Market Opportunities And Strategies To 2034

Report Price : $4490.00 | Pages : 302 | Published : February 2025 | | Format : pdf

Purchase Options
Request a Sample
Request For Discount
Customise Your Report
Item added to cart!
Request For Proposal
Request For Regional Data

Need assistance or more information before the purchase?

Enquire Before Buying

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Coronavirus (COVID-19) Current Therapy Market Definition

Coronavirus (COVID-19) current therapy refers to the range of pharmaceutical treatments and therapeutic interventions used to manage and treat the symptoms of COVID-19, reduce viral load and prevent severe outcomes such as hospitalization or death. These therapies target the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) virus, associated inflammation and complications caused by the disease, aiming to improve recovery rates and minimize long-term health impacts.  

The coronavirus (COVID-19) current therapy market consists of sales, by entities (organizations, sole traders, or partnerships), of coronavirus (COVID-19) current therapy that are utilized by a wide demographic of patients diagnosed with the virus, encompassing mild, moderate and severe cases. These treatments are employed in both acute and long-term care scenarios, ranging from early-stage intervention to advanced care for critically ill patients. The therapies are often used in combination with supportive measures such as oxygen therapy, mechanical ventilation and other critical care practices, complementing the mainstay antiviral and anti-inflammatory drugs.

Coronavirus (COVID-19) Current Therapy Market Segmentation

The coronavirus (COVID-19) current therapy market is segmented by drug type, by route of administration and by end-user.

By Drug Type –

The coronavirus (COVID-19) current therapy market is segmented by drug type into:

a) Antivirals

b) Monoclonal Antibodies (Mabs)

c) Corticosteroid

d) Supplements

e) Antimalarial

a) Interferons And Interleukin Inhibitors

b) Other Anti Infections

c) Others Drug Types

The antiviral market was the largest segment of the coronavirus (COVID-19) current therapy market segmented by drug type, accounting for 29.54% or $2,766.87 million of the total in 2024. Going forward, the mabs segment is expected to be the fastest growing segment in the coronavirus (COVID-19) current therapy market segmented by drug type, at a CAGR of -40.94% during 2024-2029.

By Route Of Administration –

The coronavirus (COVID-19) current therapy market is segmented by route of administration into:

a) Oral

b) Intravenous

The oral market was the largest segment of the coronavirus (COVID-19) current therapy market segmented by route of administration, accounting for 64.28% or $6,021.45 million of the total in 2024. Going forward, the intravenous segment is expected to be the fastest growing segment in the coronavirus (COVID-19) current therapy market segmented by route of administration, at a CAGR of -40.16% during 2024-2029.

By End-User –

The coronavirus (COVID-19) current therapy market is segmented by end-user into:

a) Hospitals

b) Clinics

c) Home Care

d) Other End-Users

The hospitals market was the largest segment of the COVID-19 current therapy market segmented by end-user, accounting for 57.49% or $5,385.60 million of the total in 2024. Going forward, the home care segment is expected to be the fastest growing segment in the COVID-19 current therapy market segmented by end-user, at a CAGR of -42.36% during 2024-2029.

By Geography - The coronavirus (COVID-19) current therapy market is segmented by geography into:

o Asia Pacific

• China

• India

• Japan

• Australia

• Indonesia

• South Korea

o North America

• USA

• Canada

o South America

• Brazil

o Western Europe

• France

• Germany

• UK

• Italy

• Spain

o Eastern Europe

• Russia

o Middle East

o Africa

North America was the largest region in the coronavirus (COVID-19) current therapy market, accounting for 54.44% or $5,099.38 million of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the coronavirus (COVID-19) current therapy market will be North America and Western Europe where growth will be at CAGRs of -40.16% and -42.83% respectively. These will be followed by Asia-Pacific and Eastern Europe where the markets are expected to grow at CAGRs of -50.58% and -53.28% respectively.

Coronavirus (COVID-19) Current Therapy Market Competitive Landscape

Major Competitors are:

Gilead Sciences, Inc.

Merck & Co.

Regeneron Pharmaceuticals, Inc.

F. Hoffmann-La Roche AG

Ipca Laboratories Limited

Other Competitors Include:

Zydus Group

Sun Pharmaceutical Industries Limited

AbbVie Inc.

Pfizer Inc.

Glenmark Pharmaceuticals Limited

Lupin Limited

Cipla Limited

Adagio Therapeutics

Bajaj Healthcare

CSPC Pharmaceutical Group

111 Inc

Brii Bio

Pharmaceutical Commercial Group

Sinopharm Holding Co

INOVIO Pharmaceuticals

Advaccine Biopharmaceutical

Shionogi & Co., Ltd

Takeda Pharmaceutical Company

Mylab Discovery Solutions

Kalbe Farma

He Qi Group Foundation

Beijing Jinwofu Bioengineering Technology Company

Zhejiang Orient Gene Biotech Co. Ltd

Transasia Bio Medicals

Vanguard Diagnostics

HLL Lifecare Limited

Voxtur Bio Ltd

LAB-CARE Diagnostics

ImmunoScience

CPC Diagnostics

Seegene

SD Biosensor

Getein Biotech

Hangzhou Biotest Biotech

AmonMed Biotechnology

Beijing Tigsun Diagnostics

Hunan Lituo Biotechnology

Vivacheck Lab

Fujirebio

Sysmex Corporation

Atomo Diagnostics  

Siemens Healthcare Pte Ltd

Senova

LetsGetChecked

Omega Diagnostics

Abingdon Health

Babylon

Motologic

Novacyt Group

Abbott Laboratories

AstraZeneca

Mylan

Zentiva

Boehringer Ingelheim

GlaxoSmithKline

Novartis AG

Teva Pharmaceutical Industries Ltd

Sanofi

Eli Lilly and Company

Sorrento Therapeutics, Inc

Ridgeback Biotherapeutics

Veru Inc

NRx Pharmaceuticals Inc

Thermo Fisher Scientific

CytoDyn

Atea Pharmaceuticals Inc

Amarin Corporation

Alexion Pharmaceuticals

Roivant Sciences

Johnson & Johnson Ltd

Genentech Inc.  

Moderna

Abdi Ibrahim Pharmaceuticals

Julphar

G42 Healthcare

SaudiVax

ViroBlock

CapeBio

Astel Diagnostics

Canary Health Technologies

BioMedomics

CTK Biotech

Book your 30 minutes free consultation with our research experts

Contact Us

Coronavirus (COVID-19) Current Therapy Market Size

The global coronavirus (COVID-19) current therapy market reached a value of nearly $9,367.71 million in 2024. The market is expected to grow from $9,367.71 million in 2024 to $541.44 million in 2029 at a rate of -43.46%. The market is then expected to grow at a CAGR of -100% from 2029.

Growth in the historic period resulted from the new COVID-19 strains and impact of COVID-19 pandemic, increasing adoption of telemedicine, expanding clinical trials and rising vaccination programs. Factors that negatively affected growth in the historic period were regulatory hurdles.

Going forward, the rising prevalence of chronic diseases, increasing aging population, increase in healthcare expenditure and favorable government initiatives will drive the growth. Factor that could hinder the growth of the coronavirus (COVID-19) current therapy market in the future include high cost of therapies and decline in demand for COVID-19 therapeutics.  

Coronavirus (COVID-19) Current Therapy Market Drivers

The key drivers of the coronavirus (COVID-19) current therapy market include:

Rising Prevalence Of Chronic Diseases

The rising prevalence of chronic diseases is expected to propel the growth of the coronavirus (COVID-19) current therapy market during the forecast period. Chronic conditions such as diabetes, cardiovascular diseases and respiratory disorders compromise the immune system, increasing the risk of severe COVID-19 outcomes. As the prevalence of these chronic conditions continues to rise, there is a growing need for effective therapies that can address the unique challenges faced by at-risk populations. For instance, according to the National Library of Medicine, a US-based agency, the number of people in the USA aged 50 and older who have at least one chronic condition will increase to 142.66 million by 2050.  Additionally, as of 2023, according to the World Health Organization, non-communicable diseases (NCDs) or chronic diseases account for 41 million deaths every year globally, which is 74% of all deaths. There were 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases and 2.0 million deaths from diabetes.   Therefore, the rising prevalence of chronic diseases will drive the growth of the coronavirus (COVID-19) current therapy market.

Coronavirus (COVID-19) Current Therapy Market Restraints

The key restraints on the coronavirus (COVID-19) current therapy market include:

High Cost Of Therapies

High cost of therapies is expected to restrain the growth of the coronavirus (COVID-19) current therapy market during the forecast period. Advanced therapies, including monoclonal antibodies, gene therapies and personalized medicine, are often associated with high production costs, rigorous clinical trials and complex manufacturing processes. Monoclonal antibodies (mAbs) are one of the most powerful tools in modern medicine, offering a highly specific and effective treatment for a range of conditions from infectious diseases like COVID-19 to chronic illnesses such as cancer and autoimmune disorders. For instance, in November 2024, a single course of monoclonal antibody therapy can cost between $1,500 and $2,500, making widespread distribution challenging.  Therefore, the high cost of therapies is expected to hamper the growth of the coronavirus (COVID-19) current therapy market.

Coronavirus (COVID-19) Current Therapy Market Trends

Major trends shaping the coronavirus (COVID-19) current therapy market include:

Strategic Investments Driving COVID-19 Therapy Market Growth

Major companies operating in the coronavirus (COVID-19) current therapy market are focusing on strategic investments to accelerate the development of effective therapies and expand clinical research. Strategic investments drive the growth of the coronavirus (COVID-19) current therapy market by boosting funding for research and development, allowing manufacturers to develop more efficient and advanced antiviral therapies.  For example, in August 2024, Apple Tree Partners (ATP), a US-based life sciences venture capital firm announced an investment of $55 million in a biotechnology startup Red Queen Therapeutics Inc., specializing in the development of antiviral therapies designed to target multiple virus families. This strategic investment underscores ATP's dedication to fostering innovation and advancing cutting-edge therapeutic solutions within the life sciences industry. Red Queen leverages a cutting-edge stapled lipopeptide platform to enable the swift development of antiviral therapies. This innovative technology targets the inhibition of viral fusion, a critical stage in the infection process. The company achieved a significant milestone by completing a successful Phase 1 clinical trial for its lead candidate, RQ-01 (a novel antiviral therapeutic), designed to combat COVID-19.

Advancements In Antiviral Drug Development For COVID-19 Treatment

Companies operating in the coronavirus (COVID-19) current therapy market are focusing on developing antiviral drugs to address the evolving needs of patients and enhance therapeutic outcomes. Antiviral drugs are specialized treatments developed to combat viral infections by disrupting the replication and spread of viruses within the body. Antiviral drugs are uniquely tailored to target viruses. For instance, in May 2023, Pfizer Inc., a US-based pharmaceutical company received approval from the U.S. Food and Drug Administration (FDA) for the oral antiviral treatment, PAXLOVID. This drug is used for the treatment of adults with mild-to-moderate COVID-19 who are at high risk of severe outcomes, including hospitalization or death. Clinical studies have shown that PAXLOVID significantly reduces the risk of hospitalization or death by approximately 86% when administered within five days of symptom onset.

Opportunities And Recommendations In The Coronavirus (COVID-19) Current Therapy Market

Opportunities – The top opportunities in the coronavirus (COVID-19) current therapy markets segmented by drug type will arise in the supplements segment, which will gain $-80.63 million of global annual sales by 2029. The top opportunities in the coronavirus (COVID-19) current therapy market segmented by route of administration will arise in the intravenous segment, which will gain $-3,089.50 million of global annual sales by 2029. The top opportunities in the coronavirus (COVID-19) current therapy markets segmented by end-user will arise in the other end-users segment, which will gain $-827.84 million of global annual sales by 2029. The coronavirus (COVID-19) current therapy market size will gain the most in Indonesia at $-32.30 million.

Recommendations- To take advantage of the opportunities, The Business Research Company recommends the COVID-19 current therapy companies to focus on strategic investments and R&D for growth, focus on developing targeted antiviral therapies, focus on innovating digital platforms for enhanced patient care, focus on the "others" anti-infections segment, focus on the oral segment, expand in emerging markets, focus on expanding distribution channels to enhance accessibility, focus on strategic pricing to maximize market penetration, focus on building trust and credibility for COVID-19 therapy companies, focus on strategic partnerships with healthcare providers and insurers to boost product adoption and focus on the home care market.

    Table Of Contents

    1 Executive Summary

    1.1 Coronavirus (COVID-19) Current Therapy – Market Attractiveness And Macro economic Landscape

    2 Table Of Contents

    3 List Of Tables

    4 List Of Figures

    5 Report Structure

    6 Market Characteristics

    6.1 General Market Definition

    6.2 Summary

    6.3 Coronavirus (COVID-19) Current Therapy Market Definition And Segmentations

    6.4 Market Segmentation By Drug Type

    6.4.1 Antivirals

    6.4.2 Monoclonal Antibodies (Mabs)

    6.4.3 Corticosteroid

    6.4.4 Supplements

    6.4.5 Antimalarial

    6.4.6 Interferons And Interleukin Inhibitors

    6.4.7 Other Anti Infections

    5.4.8 Others

    6.5 Market Segmentation By Route Of Administration

    6.5.1 Oral

    6.5.2 Intravenous

    6.6 Market Segmentation By End-User

    6.6.1 Hospitals

    6.6.2 Clinics

    6.6.3 Home Care

    6.6.4 Other End-Users

    7 Major Market Trends

    7.1 Strategic Investments Driving COVID-19 Therapy Market Growth

    7.2 Advancements In Antiviral Drug Development For COVID-19 Treatment

    7.3 Digital Solutions Transforming Healthcare Accessibility

    8 Coronavirus (COVID-19) Current Therapy Market - Macro Economic Scenario

    8.1 COVID-19 Impact On The Coronavirus (COVID-19) Current Therapy Market

    8.2 Impact Of The War In Ukraine On The Coronavirus (COVID-19) Current Therapy Market

    8.3 Impact Of High Inflation On The Coronavirus (COVID-19) Current Therapy Market

    9 Global Market Size and Growth

    9.1 Market Size

    9.2 Historic Market Growth, 2019 – 2024, Value ($ Million)

    9.2.1 Market Drivers 2019 – 2024

    9.2.2 Market Restraints 2019– 2024

    9.3 Forecast Market Growth, 2024 – 2029, 2034F Value ($ Million)

    9.3.1 Market Drivers 2024 – 2029

    9.3.2 Market Restraints 2024 – 2029

    10 Global Coronavirus (COVID-19) Current Therapy Market Segmentation

    10.1 Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    10.2 Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    10.3 Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    11 Coronavirus (COVID-19) Current Therapy Market, Regional and Country Analysis

    11.1 Global Coronavirus (COVID-19) Current Therapy Market, By Region, Historic and Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    11.2 Global Coronavirus (COVID-19) Current Therapy Market, By Country, Historic and Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    12 Asia-Pacific Market

    12.1 Summary

    12.1.1 Market Overview

    12.1.2 Region Information

    12.1.3 Market Information

    12.1.4 Background Information

    12.1.5 Government Initiatives

    12.1.6 Regulations

    12.1.7 Regulatory Bodies

    12.1.8 Major Associations

    12.1.9 Taxes Levied

    12.1.10 Corporate Tax Structure

    12.1.11 Investments

    12.1.12 Major Companies

    12.2 Asia-Pacific Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    12.3 Asia-Pacific Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    12.4 Asia-Pacific Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    12.5 Asia-Pacific Coronavirus (COVID-19) Current Therapy Market: Country Analysis

    12.6 China Market

    12.7 Summary

    12.7.1 Market Overview

    12.7.2 Country Information

    12.7.3 Market Information

    12.7.4 Background Information

    12.7.5 Government Initiatives

    12.7.6 Regulations

    12.7.7 Regulatory Bodies

    12.7.8 Major Associations

    12.7.9 Taxes Levied

    12.7.10 Corporate Tax Structure

    12.7.11 Investments

    12.7.12 Major Companies

    12.8 China Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    12.9 China Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    12.10 China Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    12.11 India Market

    12.12 India Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    12.13 India Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    12.14 India Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    12.15 Japan Market

    12.16 Japan Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    12.17 Japan Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    12.18 Japan Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    12.19 Australia Market

    12.20 Australia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    12.21 Australia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    12.22 Australia Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    12.23 Indonesia Market

    12.24 Indonesia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    12.25 Indonesia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    12.26 Indonesia Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    12.27 South Korea Market

    12.28 South Korea Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    12.29 South Korea Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    12.30 South Korea Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    13 Western Europe Market

    13.1 Summary

    13.1.1 Market Overview

    13.1.2 Region Information

    13.1.3 Market Information

    13.1.4 Background Information

    13.1.5 Government Initiatives

    13.1.6 Regulations

    13.1.7 Regulatory Bodies

    13.1.8 Major Associations

    13.1.9 Taxes Levied

    13.1.10 Corporate Tax Structure

    13.1.11 Investments

    13.1.12 Major Companies

    13.2 Western Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    13.3 Western Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    13.4 Western Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    13.5 UK Market

    13.6 UK Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    13.7 UK Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    13.8 UK Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    13.9 Germany Market

    13.10 Germany Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    13.11 Germany Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    13.12 Germany Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    13.13 France Market

    13.14 France Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    13.15 France Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    13.16 France Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    13.17 Italy Market

    13.18 Italy Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    13.19 Italy Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    13.20 Italy Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    13.21 Spain Market

    13.22 Spain Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    13.23 Spain Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    13.24 Spain Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    14 Eastern Europe Market

    14.1 Summary

    14.1.1 Market Overview

    14.1.2 Region Information

    14.1.3 Market Information

    14.1.4 Background Information

    14.1.5 Government Initiatives

    14.1.6 Regulations

    14.1.7 Regulatory Bodies

    14.1.8 Major Associations

    14.1.9 Taxes Levied

    14.1.10 Corporate Tax Structure

    14.1.11 Investments

    14.1.12 Major Companies

    14.2 Eastern Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    14.3 Eastern Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    14.4 Eastern Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    14.5 Russia Market

    14.6 Russia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    14.7 Russia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    14.8 Russia Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    15 North America Market

    15.1 Summary

    15.1.1 Market Overview

    15.1.2 Region Information

    15.1.3 Market Information

    15.1.4 Background Information

    15.1.5 Government Initiatives

    15.1.6 Regulations

    15.1.7 Regulatory Bodies

    15.1.8 Major Associations

    15.1.9 Taxes Levied

    15.1.10 Corporate Tax Structure

    15.1.11 Investments

    15.1.12 Major Companies

    15.2 North America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    15.3 North America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    15.4 North America Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    15.5 North America Coronavirus (COVID-19) Current Therapy Market: Country Analysis

    15.6 USA Market

    15.7 Summary

    15.7.1 Market Overview

    15.7.2 Country Information

    15.7.3 Market Information

    15.7.4 Background Information

    15.7.5 Government Initiatives

    15.7.6 Regulations

    15.7.7 Regulatory Bodies

    15.7.8 Major Associations

    15.7.9 Taxes Levied

    15.7.10 Corporate Tax Structure

    15.7.11 Investments

    15.7.12 Major Companies

    15.8 USA Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    15.9 USA Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    15.10 USA Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    15.11 Canada Market

    15.12 Canada Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    15.13 Canada Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    15.14 Canada Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    16 South America Market

    16.1 Summary

    16.1.1 Market Overview

    16.1.2 Region Information

    16.1.3 Market Information

    16.1.4 Background Information

    16.1.5 Government Initiatives

    16.1.6 Regulations

    16.1.7 Regulatory Bodies

    16.1.8 Major Associations

    16.1.9 Taxes Levied

    16.1.10 Corporate Tax Structure

    16.1.11 Investments

    16.1.12 Major Companies

    16.2 South America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    16.3 South America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    16.4 South America Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    17 Middle East Market

    17.1 Summary

    17.1.1 Market Overview

    17.1.2 Region Information

    17.1.3 Market Information

    17.1.4 Background Information

    17.1.5 Government Initiatives

    17.1.6 Regulations

    17.1.7 Regulatory Bodies

    17.1.8 Major Associations

    17.1.9 Taxes Levied

    17.1.10 Corporate Tax Structure

    17.1.11 Investments

    17.1.12 Major Companies

    17.2 Middle East Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    17.3 Middle East Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    17.4 Middle East Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    18 Africa Market

    18.1 Summary

    18.1.1 Market Overview

    18.1.2 Region Information

    18.1.3 Market Information

    18.1.4 Background Information

    18.1.5 Government Initiatives

    18.1.6 Regulations

    18.1.7 Regulatory Bodies

    18.1.8 Major Associations

    18.1.9 Taxes Levied

    18.1.10 Corporate Tax Structure

    18.1.11 Major Companies

    18.2 Africa Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    18.3 Africa Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    18.4 Africa Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

    19 Competitive Landscape And Company Profiles

    19.1 Company Profiles

    19.2 Gilead Sciences, Inc

    19.2.1 Company Overview

    19.2.2 Products And Services

    19.2.3 Financial Overview

    19.3 Merck & Co., Inc.

    19.3.1 Company Overview

    19.3.2 Products And Services

    19.3.3 Business Strategy

    19.3.4 Financial Overview

    19.4 Regeneron Pharmaceuticals Inc

    19.4.1 Company Overview

    19.4.2 Products And Services

    19.4.3 Business Strategy

    19.4.4 Financial Overview

    19.5 F. Hoffman-La Roche Ltd

    19.5.1 Company Overview

    19.5.2 Products And Services

    19.5.3 Business Strategy

    19.5.4 Financial Overview

    19.6 Ipca Laboratories Limited

    19.6.1 Company Overview

    19.6.2 Products And Services

    19.6.3 Financial Overview

    20 Other Major And Innovative Companies

    20.1 Zydus Group

    20.1.1 Company Overview

    20.1.2 Products and Services

    20.2 Sun Pharmaceutical Industries Limited

    20.2.1 Company Overview

    20.2.2 Products and Services

    20.3 AbbVie Inc

    20.3.1 Company Overview

    20.3.2 Products and Services

    20.4 Pfizer Inc

    20.4.1 Company Overview

    20.4.2 Products and Services

    20.5 Glenmark Pharmaceuticals Limited

    20.5.1 Company Overview

    20.5.2 Products and Services

    20.6 Eli Lilly and Company

    20.6.1 Company Overview

    20.6.2 Products and Services

    20.7 Sanofi SA

    20.7.1 Company Overview

    20.7.2 Products and Services

    20.8 GSK (GlaxoSmithKline)

    20.8.1 Company Overview

    20.8.2 Products and Services

    20.9 Novavax Inc

    20.9.1 Company Overview

    20.9.2 Products and Services

    20.10 AstraZeneca

    20.10.1 Company Overview

    20.10.2 Products and Services

    20.11 Johnson & Johnson

    20.11.1 Company Overview

    20.11.2 Products and Services

    20.12 Moderna Inc

    20.12.1 Company Overview

    20.12.2 Products and Services

    20.13 CureVac N.V.

    20.13.1 Company Overview

    20.13.2 Products and Services

    20.14 Wallace Pharmaceuticals, Inc

    20.14.1 Company Overview

    20.14.2 Products and Services

    20.15 Clover Biopharmaceuticals Ltd

    20.15.1 Company Overview

    20.15.2 Products and Services

    21 Competitive Benchmarking

    22 Competitive Dashboard

    23 Key Mergers And Acquisitions

    23.1 GSK Acquires CureVac

    23.2 FSII-Pardes Biosciences Merger Aims To Enhance COVID-19 Antiviral Therapy Capabilities

    24 Opportunities And Strategies

    24.1 Global Coronavirus (COVID-19) Current Therapy Market In 2029 – Growth Strategies

    24.1.1 Market Trend Based Strategies

    24.1.2 Competitor Strategies

    25 COVID-19 Current Therapy Market, Conclusions And Recommendations

    25.1 Conclusions

    25.2 Recommendations

    25.2.1 Product

    25.2.2 Place

    25.2.3 Price

    25.2.4 Promotion

    25.2.5 People

    26 Appendix

    26.1 Geographies Covered

    26.2 Market Data Sources

    26.3 Research Methodology

    26.4 Currencies

    26.5 The Business Research Company

    26.6 Copyright and Disclaimer

List Of Tables

    Table 1: Global Coronavirus (COVID-19) Current Therapy Market, Historic, 2019 – 2024, $ Million
  • Table 2: Global Coronavirus (COVID-19) Current Therapy Market, Forecast, 2024 – 2029, 2034F , $ Million
  • Table 3: Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 4: Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 5: Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 6: Global Coronavirus (COVID-19) Current Therapy Market, By Region, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 7: Global Coronavirus (COVID-19) Current Therapy Market, By Country, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 8: Asia-Pacific GDP Per Capita, By Country, 2019-2024, $
  • Table 9:  Asia-Pacific Population, By Country, 2019-2029, Millions
  • Table 10: Asia-Pacific Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 11: Asia-Pacific Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 12: Asia-Pacific Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 13: China GDP Per Capita, 2019-2024, $
  • Table 14:  China Population, 2019-2029, Millions
  • Table 15: China Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 16: China Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 17: China Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 18: India Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 19: India Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 20: India Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 21: Japan Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 22: Japan Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 23: Japan Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 24: Australia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 25: Australia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 26: Australia Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 27: Indonesia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 28: Indonesia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 29: Indonesia Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 30: South Korea Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 31: South Korea Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 32: South Korea Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 33: Western Europe GDP Per Capita, By Country, 2019-2024, $
  • Table 34:  Western Europe Population, By Country, 2019-2029, Millions
  • Table 35: Western Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 36: Western Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 37: Western Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 38: UK Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 39: UK Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 40: UK Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 41: Germany Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 42: Germany Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 43: Germany Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 44: France Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 45: France Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 46: France Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 47: Italy Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 48: Italy Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 49: Italy Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 50: Spain Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 51: Spain Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 52: Spain Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 53: Eastern Europe GDP Per Capita, By Country, 2019-2024, $
  • Table 54:  Eastern Europe Population, By Country, 2019-2029, Millions
  • Table 55: Eastern Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 56: Eastern Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 57: Eastern Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 58: Russia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 59: Russia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 60: Russia Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 61: North America GDP Per Capita, By Country, 2019-2024, $
  • Table 62:  North America Population, By Country, 2019-2029, Millions
  • Table 63: North America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 64: North America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 65: North America Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 66: USA GDP Per Capita, 2019-2024, $
  • Table 67:  USA Population, 2019-2029, Millions
  • Table 68: USA Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 69: USA Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 70: USA Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 71: Canada Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 72: Canada Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 73: Canada Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 74: South America GDP Per Capita, By Country, 2019-2024, $
  • Table 75:  South America Population, By Country, 2019-2029, Millions
  • Table 76: South America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 77: South America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 78: South America Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 79: Middle East GDP Per Capita, By Country, 2019-2024, $
  • Table 80:  Middle East Population, By Country, 2019-2029, Millions
  • Table 81: Middle East Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 82: Middle East Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 83: Middle East Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 84: Africa GDP Per Capita, By Country, 2019-2024, $
  • Table 85:  Africa Population, By Country, 2019-2029, Millions
  • Table 86: Africa Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 87: Africa Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 88: Africa Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Table 89: Global Coronavirus (COVID-19) Current Therapy Market, Key Competitor Estimated Market Shares, 2023, Percentage (%)
  • Table 90: Gilead Sciences, Inc – Financial Overview, 2023, $Million
  • Table 91: Merck & Co., Inc – Financial Overview, 2019 – 2023, $Billion
  • Table 92: Regeneron Pharmaceuticals Inc – Financial Overview, 2019 – 2023, $Billion
  • Table 93: F. Hoffmann-La Roche Ltd – Financial Overview, 2019 – 2023, $Billion
  • Table 94: Ipca Laboratories Limited – Financial Overview, 2019 – 2023, $ Billion
  • Table 95: Coronavirus (COVID-19) Current Therapy Market, Competitive Benchmarking (In USD Millions)
  • Table 96: Coronavirus (COVID-19) Current Therapy Market, Competitive Dashboard
  • Table 97: Coronavirus (COVID-19) Current Therapy Market Data Sources

List Of Figures

    Figure 1: Global Coronavirus (COVID-19) Current Therapy Market Segmentation By Drug Type
  • Figure 2: Global Coronavirus (COVID-19) Current Therapy Market Segmentation By Route Of Administration
  • Figure 3: Global Coronavirus (COVID-19) Current Therapy Market Segmentation By End-User
  • Figure 4: Global Coronavirus (COVID-19) Current Therapy Market, Historic, 2019 – 2024, $ Million
  • Figure 5: Global Coronavirus (COVID-19) Current Therapy Market, Forecast, 2024 – 2029, 2034F, $ Million
  • Figure 6: Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 7: Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 8: Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 9: Global Coronavirus (COVID-19) Current Therapy Market, By Region, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 10: Global Coronavirus (COVID-19) Current Therapy Market, By Country, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 11: Asia-Pacific Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 12: Asia-Pacific Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 13: Asia-Pacific Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 14: China Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 15: China Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 16: China Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 17: India Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 18: India Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 19: India Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 20: Japan Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 21: Japan Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 22: Japan Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 23: Australia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 24: Australia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 25: Australia Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 26: Indonesia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 27: Indonesia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 28: Indonesia Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 29: South Korea Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 30: South Korea Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 31: South Korea Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 32: Western Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 33: Western Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 34: Western Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 35: UK Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 36: UK Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 37: UK Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 38: Germany Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 39: Germany Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 40: Germany Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 41: France Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 42: France Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 43: France Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 44: Italy Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 45: Italy Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 46: Italy Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 47: Spain Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 48: Spain Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 49: Spain Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 50: Eastern Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 51: Eastern Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 52: Eastern Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 53: Russia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 54: Russia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 55: Russia Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 56: North America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 57: North America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 58: North America Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 59: USA Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 60: USA Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 61: USA Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 62: Canada Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 63: Canada Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 64: Canada Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 65: South America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 66: South America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 67: South America Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 68: Middle East Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 69: Middle East Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 70: Middle East Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 71: Africa Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 72: Africa Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 73: Africa Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
  • Figure 74: Global Coronavirus (COVID-19) Current Therapy Market, Key Competitor Estimated Market Shares, 2023, Percentage (%)
  • Figure 75: Gilead Sciences, Inc – Financial Overview, 2019 – 2023, $ Billion
  • Figure 76: Merck & Co., Inc – Financial Overview, 2019 – 2023, $ Billion
  • Figure 77: Regeneron Pharmaceuticals Inc – Financial Overview, 2019 – 2023, $ Billion
  • Figure 78: F. Hoffmann-La Roche Ltd – Financial Overview, 2019 – 2023, $ Billion
  • Figure 79: Ipca Laboratories Limited – Financial Overview, 2019 – 2023, $ Billion
  • Figure 80: Geographic Regions Covered

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

Read More

Global Cancer Immunotherapy Market Overview And Prospects – Includes Cancer Immunotherapy Market Share

Read More

How Will The Biosimilar Interleukins Market Grow In 2022?

Read More

Latest Cancer Clinical Decision Tools Market Growth Study 2022-2026 By The Business Research Company

Read More

Latest Digestive Health Supplements Market Growth Study 2022-2026 By The Business Research Company

Read More

The Business Research Company offers the nucleic acid based gene therapy market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the radiopharmaceuticals market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the pegfilgrastim biosimilars market market research report 2022 with industry size, share, segments and market growth

Read More

Central Nervous System Drugs Market 2021 - By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other CNS Drugs), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Intravenous, Intranasal/ Inhalation), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Over-The-Counter Drugs, Prescription-Based Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2030

View Report

CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By Region, Opportunities And Strategies – Global Forecast To 2030

View Report

Pharmaceutical Drugs Market 2024 – By Type (Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorder Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Disease Drugs, Vaccine, Therapeutic Nutrients And Mineralsa) Cardiovascular Drugs Type (Anti-Hypertensive Drugs, Hypolipidemics, Anti-Thrombotic, Angina Pectoris, Congestive Heart Failure, Other Cardiovascular Drugsb) Dermatology Drugs Type (Acne Drugs, Dermatitis Drugs, Psoriasis Drugs, Other Drugs For Dermatology Diseasesc) Gastrointestinal Drugs Type (Antacids, Antiulcerants, Antiemetics And Antinauseants, Antidiarrhealsd) Genito-Urinary Drugs Type (Hormonal Contraceptives, Drugs For Benign Prostatic Hypertrophy, Drugs For Infertility, Drugs For Erectile Dysfunction

View Report

Oncology Drugs Market 2023 – By Type (Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Cancer, Cervical Cancer, Blood Cancer, Other Oncology Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/Drug Stores, Other Distribution Channels), By Route Of Administration (Oral, Parental, Other Route Of Administration), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2032

View Report

Dry Eye Medication Market 2021 - By Prescription Type (OTC Drugs, Prescription Drugs) By Drug Variation (Branded, Generic) By Type Of Product (Aqueous, Evaporative, Aqueous And Evaporative) By Distribution Channel (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies) By Delivery System (Liquid, Gel, Ointment) And By Region, Opportunities And Strategies – Global Forecast To 2030

View Report

Respiratory Diseases Drugs Global Market Report 2022 – By Type (Anti-Asthmatics And COPD Drugs, Cough And Cold Preparations), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026

View Report

Gastrointestinal Drugs Global Market Report 2022 – By Type (Antacids, Antiulcerants, Vitamin And Minerals, Antiobesity, Antiemetics And Antinauseants, Antidiarrhoeals), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026

View Report

Hematology Drugs Global Market Report 2022 – By Type (Blood Products, Anemia And Other Blood Disorder Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026

View Report